CoChat

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome

Open access
Dawson, Alison J., Sathyapalan, Thozhukat, Vince, Rebecca, Coady, Anne-Marie, Ajjan, Ramzi A., Kilpatrick, Eric S., Atkin, Stephen L. · 2019 · Frontiers in Endocrinology
Cited by 33

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Polycystic ovary syndrome (PCOS) is associated with an adverse cardiovascular risk profile including a prothrombotic state. Exenatide has been shown to be effective at improving insulin sensitivity and weight loss in PCOS; therefore this study was undertaken to assess its effects on weight, endothelial function, inflammatory markers, and fibrin structure/function in overweight/obese women with PCOS. Methods: Thirty overweight/obese anovulatory women with all 3 Rotterdam criteria received exenatide 5mcg bd for 4 weeks then 10mcg bd for 12 weeks. The primary outcome was change in weight; secondary outcomes were changes in endothelial function (Reactive Hyperemia-Peripheral Arterial Tonometry (RH-PAT)), serum endothelial markers (ICAM-1, VCAM-1, E-selectin and P-selectin), change in inflammation (hsCRP), and alteration in clot structure and function (maximum absorbance (MA), and time from full clot formation to 50% lysis (LT)). Results: Twenty patients completed the study. Exenatide reduced weight 111.8±4.8kg to 108.6±4.6kg p=0.003. Serum endothelial markers changed with a reduction in ICAM (247.2±12.9 to 231.3±11.5ng/ml p=0.02), p-selectin (101.1±8.2 to 87.4±6.6 ng/ml p=0.01) and e-selectin (38.5±3.3 to 33.6±2.6 ng/ml p=0.03), without an overt change in endothelial function. Inflammation improved (CRP; 8.5±1.4 to 5.6±0.8 mmol/L p=0.001), there was a reduction in clot function (LT; 2987±494 to 1926±321s p=0.02) but not clot structure. Conclusion: Exenatide caused a 3% reduction in weight, improved serum markers of endothelial function, inflammation and clot function reflecting an improvement in cardiovascular risk indices in these women with PCOS. This suggests exenatide could be an effective treatment for obese women with PCOS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2019.00189

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 33

Metadata

Authors
Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L.
Venue
Frontiers in Endocrinology
Published
2019-04-02
Volume
10
Pages
189-189
ISSN
1664-2392 (ISSN-L)
OpenAlex
W2925508960
Cited by
33
References
7
FWCI
2.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.3389/fendo.2019.00189
The paper
Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L. (2019). The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2019.00189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.